Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Eterna Therapeutics Inc (ERNA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ERNA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -59.95% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 13.62M USD | Price to earnings Ratio - | 1Y Target Price 3 |
Price to earnings Ratio - | 1Y Target Price 3 | ||
Volume (30-day avg) - | Beta 7.12 | 52 Weeks Range 1.75 - 39.45 | Updated Date 06/29/2025 |
52 Weeks Range 1.75 - 39.45 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -32.7 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2652.9% |
Management Effectiveness
Return on Assets (TTM) -32.42% | Return on Equity (TTM) -2264.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 14647264 | Price to Sales(TTM) 25.45 |
Enterprise Value 14647264 | Price to Sales(TTM) 25.45 | ||
Enterprise Value to Revenue 27.38 | Enterprise Value to EBITDA -0.29 | Shares Outstanding 7361200 | Shares Floating 1664157 |
Shares Outstanding 7361200 | Shares Floating 1664157 | ||
Percent Insiders 61.04 | Percent Institutions 1.35 |
Upturn AI SWOT
Eterna Therapeutics Inc
Company Overview
History and Background
Eterna Therapeutics Inc. is a biotechnology company focusing on developing messenger ribonucleic acid (mRNA) therapies for treating diseases. Founded in 2015 as Sinobiomed, changed its name to Eterna Therapeutics, Inc. in 2021. Significant milestones include advancing lead candidates into clinical trials and securing strategic partnerships.
Core Business Areas
- mRNA Therapeutics: Development of mRNA-based drugs for various diseases, including oncology, infectious diseases, and rare genetic disorders.
Leadership and Structure
The leadership team consists of experienced executives in the biotechnology and pharmaceutical industries. The organizational structure includes research and development, clinical operations, and business development departments.
Top Products and Market Share
Key Offerings
- ETERNA-001: A lead mRNA candidate targeting solid tumors. Currently in Phase I clinical trials. Market share is not currently available. Competitors include Moderna (MRNA) and BioNTech (BNTX).
Market Dynamics
Industry Overview
The mRNA therapeutics market is rapidly growing, driven by the success of mRNA vaccines and the potential to address a wide range of diseases.
Positioning
Eterna Therapeutics Inc. is positioned as an emerging player in the mRNA therapeutics market, focusing on novel applications and differentiated delivery technologies. They have a competitive advantage through their proprietary delivery methods.
Total Addressable Market (TAM)
The global mRNA therapeutics market is projected to reach billions of dollars. Eterna Therapeutics Inc. is positioning itself to capture a significant share of this expanding market. The current market size is around $59 billion and is expected to grow over 14.2% by 2031 to $215 Billion.
Upturn SWOT Analysis
Strengths
- Proprietary mRNA delivery technologies
- Strong preclinical data
- Experienced leadership team
- Focus on high-value therapeutic areas
Weaknesses
- Limited clinical data
- Reliance on external funding
- Smaller size compared to established competitors
- Early stage of development
Opportunities
- Strategic partnerships with larger pharmaceutical companies
- Expansion of pipeline into new therapeutic areas
- Positive clinical trial results
- Increasing adoption of mRNA therapeutics
Threats
- Competition from established players
- Regulatory hurdles
- Clinical trial failures
- Intellectual property disputes
Competitors and Market Share
Key Competitors
- MRNA
- BNTX
- LLY
- REGN
- ABBV
Competitive Landscape
Eterna Therapeutics Inc. faces significant competition from established players with greater resources and clinical pipelines. ETRN advantages lie in novel technology and targeted approach.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's recent formation and focus on R&D.
Future Projections: Future growth is contingent on clinical trial successes and commercialization of mRNA therapies. Analyst projections are currently limited.
Recent Initiatives: Focus on advancing lead mRNA candidate ETERNA-001 into clinical trials and developing new mRNA delivery technologies. Expanded collaborations
Summary
Eterna Therapeutics Inc. is an early-stage mRNA therapeutics company with promising technology but faces significant competition and financial challenges. Its success hinges on advancing its clinical pipeline and securing additional funding. Key strengths include its proprietary delivery technologies, while weaknesses include limited clinical data and reliance on external funding. The company needs to capitalize on opportunities through strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Industry Reports
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Market share estimates are approximate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eterna Therapeutics Inc
Exchange NASDAQ | Headquaters Cambridge, MA, United States | ||
IPO Launch date 1992-10-19 | CEO, President & Director Mr. Sanjeev Luther | ||
Sector Healthcare | Industry Biotechnology | Full time employees 6 | Website https://www.ernexatx.com |
Full time employees 6 | Website https://www.ernexatx.com | ||
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.